UBS Maintains Neutral on RXO, Raises Price Target to $31
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Joseph Parkhill maintains a Neutral rating on RXO (NYSE:RXO) and raises the price target from $22 to $31.
August 08, 2024 | 1:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS analyst Joseph Parkhill maintains a Neutral rating on RXO and raises the price target from $22 to $31.
The raised price target from $22 to $31 by UBS suggests a positive outlook for RXO, which could lead to a short-term increase in stock price despite the Neutral rating.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100